![New Alzheimer's Disease Drug Receives Full FDA Approval](https://d91ztqmtx7u1k.cloudfront.net/ClientContent/Images/Large/0570a948-5126-4414-bebf-7dc534efa49f.png)
On January 6, 2023, lecanemab (trade name Leqembi), an Alzheimer's disease drug developed by Eisai and Biogen, received conditional approval from the FDA. The results of its Phase 3 clinical trial showed that the drug slowed cognitive decline in Alzheimer's disease patients by 27%. The FDA has conducted a further review of the clinical trial results to determine whether the drug can be fully approved. Read More